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Anticancer agents interacting with membrane glucose 
transporters
† 
C. Granchi,
a
 S. Fortunato
a
 and F. Minutolo*
a 
The altered metabolism observed in cancer cells generally consists in increased glucose uptake and glycolytic activity. This 
is associated with an overexpression of glucose transporter proteins (GLUTs), which facilitate glucose uptake across the 
plasma membrane and play a crucial role in the survival of cancer cells. Therefore GLUTs are considered as suitable targets 
for the treatment of cancer. Herein we review some of the most relevant GLUT inhibitors that have been recently 
developed as perspective anticancer agents. 
Introduction 
Tumours consume huge amounts of glucose compared to healthy 
tissues, because they display a high rate of glycolysis. In order to do 
so, cancer cells generally take up sugars at a higher rate than 
normal cells. This peculiarity, which is also known as the Warburg 
effect,
1 has led to the development of imaging techniques, such as 
PET scan, that track a radioactively labelled glucose analogue, 2-
deoxy-2-(
18
F)fluoro-D-glucose (
18
F-FDG).
2,3 Hence, this metabolic 
feature has been widely exploited for the detection of cancer 
tissues, whereas attempts to do the same for therapeutic purposes 
are still in their infancy.
4-6
  
Glucose transporters (GLUTs), which are transmembrane proteins 
that facilitate the concentration-driven uptake of glucose inside the 
cell, are often overexpressed in cancer cells. Therefore, they may be 
either targeted by GLUT-inhibitors, in order to counteract the 
“tumor gluttony” mentioned above, or they may be exploited for 
the internalization of glycoconjugates anticancer agents.
7
 This 
review recapitulates some of the most significant examples of 
natural and synthetic inhibitors of the various isoforms of GLUTs, as 
well as of sugar-conjugated anticancer agents that exploit the 
Warburg effect in order to selectively target cancer cells. 
 
Natural GLUT inhibitors 
 
A large class of GLUT inhibitors is represented by flavonoids, 
polyphenolic compounds that are widely found in many fruits and 
vegetables as plant secondary metabolites, and most of them 
showed an appreciable activity on GLUTs.
8
  
Naringenin (1, Figure 1) is a flavanone found in high concentration 
in grapefruit and orange, which shows a broad range of biological 
effects: it is a well-known antioxidant, it displays anticancer 
properties,
9
 it reduces the risk of atherosclerosis,
10 it binds with 
good affinity and selectivity to estrogen receptor β,
11
 and it exerts a 
potent cardioprotective effect.
12
 In addition to these properties, it 
displayed a certain inhibitory effect on glucose uptake in myelocytic 
U937 cells (IC50 was about 50 µM).
13
 The same effect was confirmed 
in 3T3-L1 adipocytes, where naringenin blocked insulin-stimulated 
glucose uptake in a dose-dependent manner: it was calculated that 
a physiological dose of 6 µM of naringenin (for example by regular 
consumption of grapefruit juice) resulted in an inhibition of glucose 
uptake by approximately 20%.
14
 This effect was confirmed also in 
cultured cancer cells: a 100 µM concentration of naringenin 
inhibited glucose uptake by 50% and cell proliferation by 20% in 
MCF-7 breast cancer cells.
15,16 These effects were exerted by 
inhibiting the activity of phosphoinositide 3-kinase (PI3K), a key 
regulator of insulin-induced GLUT4 translocation to the cellular 
membrane, and the mitogen-activated protein kinases (MAPK) 
pathway, which regulates cellular functions including proliferation. 
However, if naringenin impaired cancer cell proliferation by 
affecting glucose uptake or the two actions are independent is still 
not well understood. A controversial effect was reported in L6 
skeletal muscle cells, in which naringenin stimulated glucose uptake 
independent of insulin and increased AMP-activated protein kinase 
(AMPK) activation and, as suggested by authors, these differences 
could be explained supposing a cell-specific effect of naringenin.
17  
Myricetin (2, Figure 1), fisetin (3, Figure 1), quercetin (4, Figure 1) 
and the glucoside of quercetin, isoquercitrin (5, Figure 1), share the 
same flavonol central scaffold and differ only for the presence of 
hydroxyl substituents or of a glucose moiety. These four flavonoids 
were found to inhibit the intestinal isoform GLUT2 by a 
noncompetitive mechanism, thus suggesting a potential use as 
antidiabetic and antiobesity agents. In particular, myricetin and 
quercetin were the most potent compounds in the inhibition of 2-
deoxyglucose and fructose uptake, with IC50 values in the range of 
12-17 µM.
18
 Quercetin proved to bind GLUT1 in the inward-facing 
conformation at a site that is accessible on the outer surface of the 
carrier.
19
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Moreover, myricetin, fisetin and quercetin, together with other 
flavonoids such as apigenin (6, Figure 1), luteolin (7, Figure 1), 
kaempferol (8, Figure 1), genistein (9, Figure 1) and silybin (10, 
Figure 1), proved to have an effect on glucose uptake in adipocytes 
involving a block of insulin-stimulated GLUT4 translocation to the 
plasma membrane.
20
 Strobel et al. reported a direct interaction of 
myricetin and quercetin with GLUT4, showing a competitive 
inhibition mechanism in adipocytes (Ki =33.5 and 16 µM, 
respectively).
21
 However, for this group of compounds no activities 
on the GLUT isoforms involved in cancer progression and 
development were described. In the same class of compounds, it is 
worth mentioning flavone apigenin (6), which inhibits GLUT1-
mediated glucose uptake in human pancreatic cancer cells, in 
adenoid cystic carcinoma and in laryngeal carcinoma and it also 
inhibits GLUT1 expression, leading to a block of proliferation by 
apoptosis. The mechanism by which apigenin inhibits GLUT1 
expression may involve the PI3K/Akt pathway, but this effect is not 
the only responsible of inhibition of glucose uptake.
22-24
  
The flavan-3-ol epigallocatechin gallate (11, Figure 1), which is the 
main polyphenol present in green tea, and quercetin (4) markedly 
inhibited 
3
H-DG uptake in estrogen receptor (ER)-positive MCF7 and 
ER-negative MDA-MB-231 human breast cancer cell lines. Both 
compounds at a concentration of 100 µM were able to reduce 
lactate production in MCF7 cells and decreased MCF7 cell viability 
and proliferation.
25
  
Kaempferol (8) was reported as a potent inhibitor of 
3
H-DG uptake 
in breast MCF-7 cells, with a IC50 value of 4 µM, showing a mixed-
type competitive behavior, moreover it decreased GLUT1 protein 
levels. This compound produced a significant increase in the 
amount of extracellular lactate by inhibiting also the reuptake of 
lactate, which is mediated by monocarboxylate transporter 1 
(MCT1), thus affecting the glycolytic metabolism of cancer cells at 
two different levels. This promising flavonol at a concentration of 
100 µM reduced cell viability and proliferation rate. The same 
effects were mimicked by low glucose conditions and were reversed 
by high concentrations of glucose, suggesting that the cytotoxic 
effects are provoked by the block of glucose uptake.
26
  
Dihydrochalcone phloretin (12, Figure 1) is found primarily in apples 
and pears and it can also be produced when its glycoside phlorizin 
(13, Figure 1) is orally consumed and subsequently nearly entirely 
converted into phloretin by hydrolytic enzymes in the small 
intestine. Phloretin strongly inhibits GLUT1 in a competitive 
manner.
27-29
 Both flavonoids, phloretin and phlorizin, were able to 
reduce tumour cell growth in vitro and in vivo and their cytotoxic 
effects were attributed to the inhibition of GLUT1.
30,31 The block of 
glucose uptake elicited by phloretin also leads to sensitization of 
cancer cells to the chemotherapeutic agent daunorubicin, inducing 
apoptosis in a synergistic manner under hypoxic conditions.
32
 
Phloretin induces apoptosis in HepG2 cells overexpressing GLUT2, 
which was reversed by glucose pretreatment. The same effect was 
induced by GLUT2 siRNA knockdown, suggesting that the cytotoxic 
action of phloretin involves the inhibition of GLUT2. Phloretin was 
administered in HepG2 xenografts and a reduction of final tumor 
weight and a severe decrease in 
18
F-FDG uptake by PET studies 
were observed without apparent toxicity, thus confirming the 
efficacy in vivo of this flavonoid in hepatoma cells.
33
  
Isoflavone genistein (9) is commonly known as a tyrosine kinase 
inhibitor, but it was also reported as a competitive GLUT1 inhibitor 
(Ki of 7 µM) in human myeloid HL-60 cells, CHO-1 cells 
overexpressing GLUT1, and human erythrocytes, as well as a GLUT4 
inhibitor in T3-L1 adipocytes (IC50 of 20 µM), although it cannot be 
considered as a specific inhibitor since it affects many other cellular 
activities.
34,35 Kinetic studies on GLUT1 showed that genistein binds 
the transporter in the outward-facing conformation in a site that 
partially overlaps the external binding site of glucose.
19
  
Phloretin, apigenin, and the two isoflavones daidzein (14, Figure 1) 
and genistein (9) were tested in androgen-sensitive (LNCaP) and -
insensitive (PC-3) prostate cancer cells: GLUT protein levels are 
higher in androgen-insensitive PC-3 cells and therefore the four 
flavonoids inhibited cell growth more efficiently in LNCaP cells, 
where they modulate GLUT1 and GLUT4 expression and regulate 
glucose uptake in a quite complex manner, depending on 
androgenic signaling and incubation time. The direct interaction of 
these four compounds with GLUTs was supported by docking 
studies, which were performed in a model of the xylose transporter 
XylE crystallized from E. coli: they bind in a region of the receptor 
located near the active site present in both GLUT1 and GLUT4, thus 
hindering the glucose binding.
36 The GLUT-inhibitory activity of 
daidzein, which differs from genistein since it lacks one hydroxyl 
group, is still controversial due to contrasting data, 
34,37
 although 
Cheong et al. observed an antihyperglycemic effect produced by 
daidzein, through an enhanced glucose uptake caused by GLUT4 
translocation to plasma membrane in muscle cells and a 
subsequent suppression of the rises in blood glucose levels in 
vivo.
38 
 
The flavonoid silybin (10, known also as silibinin) is the major active 
constituent of the extract milk thistle (Silybum marianum) and it has 
been used for the treatment of liver diseases. Silybin, together with 
its oxidized form 2,3-dehydrosilybin, are competitive inhibitors of 
GLUT4 (Ki = 60 and 114 µM, respectively, in 3T3-L1 adipocytes), 
blocking glucose uptake and impairing cell viability in cancer cell 
lines.
39
 A phase I trial of silybin for the treatment of prostate cancer 
was completed in 2008, however this compound did not show an 
adequate tissue penetration despite the high blood concentrations 
observed in patients.
40-42
 A phase I study of a phosphatidylcholine 
derivative of silybin for the treatment of advanced hepatocellular 
carcinoma was prematurely stopped, due to the occurrence of 
adverse effects, consisting of an increase in liver function 
abnormalities and inflammatory biomarkers that led to the death of 
enrolled subjects.
43
  
Xanthohumol (15, Figure 1) is a prenylated chalcone which occurs 
only in the hop plant and possesses a wide spectrum of anticancer 
activities. It proved to be a noncompetitive inhibitor of 
3
H-deoxy-D-
glucose in a human first-trimester EVT cell line (HTR-8/SVneo cells) 
with an IC50 value of 3.55 µM. Moreover, it decreased cell viability, 
proliferation and culture growth, and these effects were mimicked 
by low extracellular glucose conditions and reversed by high 
extracellular glucose conditions. However, a specific effect of 
xanthohumol on GLUT1 was not determined, although this 
transporter is highly expressed in this specific cell line and it is 
responsible for the glucose uptake in placenta during pregnancy.
44 
 
Unfortunately, although this wide class of flavonoids exerts some 
relevant activity on GLUTs, their unspecific panels of biological 
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activities make these compounds unsuitable to be developed as 
GLUT inhibitors for cancer treatment and it is difficult to discern if 
their beneficial antiproliferative activities on cancer cells derive 
from the block of glucose uptake or to their well-known antioxidant 
properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structures of flavonoids that inhibit GLUTs. 
 
Cytochalasin B (16, Figure 2) is a macrocyclic mycotoxin known as a 
GLUT inhibitor in human erythrocytes,
45,46
 and it proved to bind 
GLUT1 and GLUT4 in skeletal muscle.
47 Cytochalasin B in association 
with an OXPHOS inhibitor, such as antimycin A or leucascandrolide 
A, led to a rapid and synergistic intracellular ATP depletion in the 
highly glycolytic A549 lung carcinoma cells. A couple of derivatives 
of cytochalasin B, compounds 17 and 18 (Figure 2) that are 
noncompetitive inhibitors of GLUT1 (Ki = 1.2 and 0.8 µM for 
derivatives 17 and 18, respectively), proved to be able to suppress 
ATP synthesis when tested in combination with a blocker of 
mitochondrial function in A549 cells (IC50 = 10 and 3 µM for 
derivatives 17 and 18, respectively) and in CHO-K1 cells (IC50 = 2 and 
1 µM for derivatives 17 and 18, respectively), but also in glioma and 
prostate cancer cells, and they reduced lactate production in the 
same cell lines. The two derivatives lack any off-target effect, such 
as depolymerization of the actin cytoskeleton, which is one of the 
most serious side effect of the parent compound cytochalasin B.
48
  
Gossypol (19, Figure 2) is a natural polyphenolic binaphthyl 
disesquiterpene obtained from the cotton plant and it acts as an 
inhibitor of several dehydrogenases / protein kinases, as well as 
other various activities on many other targets. Pérez et al. identified 
gossypol as a GLUT1 inhibitor in human HL-60 cells, CHO cells, and 
human erythrocytes, with a mixed noncompetitive mechanism (Ki = 
20 µM), by interacting with the transporter on the intracellular 
portion.
49
  
Curcumin (20, Figure 2) derives from the rhizome of Curcuma longa 
and it is well known for its anti-inflammatory, anti-cancer and 
antioxidant properties. In order to investigate the exact mechanism 
of anti-cancer activity of curcumin, this natural compound was 
tested in lung cancer A549 cells and it showed an antiproliferative 
effect. Curcumin decreased cellular invasion and the expression of 
GLUT1, matrix metalloproteinase MT1-MMP and MMP2, which are 
considered as biomarkers of metastatic invasion. The anti-invasive 
effect of curcumin was impaired in GLUT1 over-expressing A549 
cells. This result was confirmed in nude mice bearing tumors 
originated from A549 cells, in which over-expression of GLUT1 
caused an increased resistance to the anti-metastatic effect of 
curcumin.
50
  
Resveratrol (21, Figure 2) is a polyphenolic compound found in 
grape skins and peanuts, which is produced in response to injury or 
when the plant is attacked by pathogens, such as bacteria or fungi. 
Resveratrol is known as an anticancer, antioxidant, 
antinflammatory, antidiabetic and antiobesity agent, but it was 
reported to display a certain effect on glucose uptake and 
metabolism. In 2001 a study performed in myelocytic cell lines 
(U937 and HL-60) revealed that most glucose uptake in these cells 
was glucose-independent and was inhibited by resveratrol involving 
a direct action on GLUT1 and GLUT3 with Ki values of 89 and 85 µM, 
respectively.
51
 Lately, the behaviour of resveratrol in these two cell 
lines and in human red cells was better analyzed, revealing a mixed 
noncompetitive mechanism. In fact, resveratrol binds to an 
endofacial site of GLUT1, displacing the binding of cytochalasin B 
form the transporter.
52
 Conversely, resveratrol produced an 
increase in glucose uptake in skeletal muscle cells. However, this 
effect did not derive from the direct interaction of this compound 
with a GLUT transporter, rather it involved sirtuin-dependent AMPK 
activation which leads to stimulation of the activity of GLUT4.
53
  
Methylxanthines, such as natural compounds caffeine (1,3,7-
trimethylxanthine, 22, Figure 2) and theophylline (1,3-
dimethylxanthin, 23, Figure 2), and synthetic derivative 
pentoxifylline [1-(5-oxohexyl)-3,7-dimethylxanthine, 24, Figure 2], 
were found to influence glucose uptake, but they also possess a 
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variety of other physiological effects. They inhibit glucose uptake in 
human red blood cells by displacing previously-bound inhibitor 
cytochalasin B, thus confirming their direct interaction with the 
transporter. Methylxanthines bind a common site on the 
extracellular surface of GLUT1, which is close to, but distinct from, 
the glucose binding site.
54
  
(+)-Cryptocaryone (25, Figure 2) is a natural compound isolated 
from tropical plants belonging to genus Cryptocarya (Lauraceae). 
Importantly, it proved to inhibit glucose uptake of about 40% at a 
concentration of 30 µM in human lung cancer H1299 cells.
55
 This 
inhibitory effect was considered to be responsible of the cytotoxic 
effect of this compound in human colon cancer HT-29 cells (IC50 = 
0.32 µM) and also in murine leukemia P-388 cells (IC50 = 0.04 µM).
56
 
In a separate study it was further investigated the mechanism of 
the antiproliferative activity in human prostate cancer PC-3 cells 
(IC50 = 1.6 µM) and it seemed induced by apoptosis through the 
activation of caspase-8 and 3.
57
 
Four ellagic acid derivatives 26-29 (Figure 2) were isolated from 
Lagerstroemia speciosa, a tree originating from tropical countries. 
All of them were tested for their ability to inhibit the uptake of 2-
deoxy-D-[
3
H]-glucose in 3T3-L1 adipocytes and proved to block the 
glucose transport with various potencies, however their exact 
mechanism of action was not further investigated.
58
  
Melatonin (30, Figure 2) is a natural compound found in animal and 
plants. In humans it is secreted by the pineal gland and regulates 
the circadian rhythms of physiological functions, but it also 
participates to many other biological effects through the activation 
of its receptors. Many studies demonstrated that melatonin may 
influence insulin secretion and glucose homeostasis. The transport 
of melatonin inside cells is facilitated thanks to the amphipathic 
nature of its structure, but Hevia et al. demonstrated that GLUT1 
was responsible of melatonin uptake into cancer cells and, in 
particular, melatonin binds the glucose binding site of the receptor. 
Differences in glucose concentrations and the presence of GLUT 
inhibitors affect the binding of melatonin. The presence of 
melatonin was observed inside human blood erythrocytes, which 
possess GLUT1 transporters, and its uptake was prevented by the 
inhibitor cytochalasin B. On the other hand, melatonin was not 
found in liposomes devoid of GLUT1. In prostate cancer LNCaP cells, 
it was observed a parallel trend for GLUT1 expression, intracellular 
concentration of melatonin and inhibition of cell proliferation. In 
order to confirm the antiproliferative effect of this compound, 
which is mediated by GLUT1, an in vivo study was performed on a 
mouse model for prostate cancer. This study revealed a longer 
survival of animals supplemented with glucose and melatonin than 
that of those supplemented only with glucose, thus confirming that 
melatonin attenuated the glucose-induced tumour growth.
59
  
Kitagawa et al. identified glucopiericidin A (GPA, 31, Figure 2), 
extracted from a microbial broth of Lechevalieria sp., in a screening 
performed to find inhibitors of epidermial growth factor (EGF)-
induced filopodia protrusion in human epidermal carcinoma A431 
cells. In a metabolomic analysis this natural compound proved to 
decrease concentrations of pyruvate and lactate, as well as the 
lactate/pyruvate ratio. The glycolytic target of 31 was identified by 
observing that GPA significantly reduced [
3
H]-2DG uptake in cells, 
with an IC50 value of 4.9 nM, a value similar to that observed in the 
inhibition of filopodia protrusion. Therefore, since GLUT1 is 
responsible for glucose uptake in A431 cells, it was hypothesized 
that GPA inhibited GLUT1 function. GPA was tested also in Swiss 
3T3-L1 adipocytes and demonstrated to inhibit the increased 
uptake of glucose in insulin-stimulated cells.
60
 
It is noteworthy to mention the anticancer activity exerted by the 
extracts of the tropical tree usually known as Graviola (Annona 
muricata), which are composed mainly of long chained fatty acid 
derivatives (Annonaceous acetogenins). These natural extracts 
reduced the viability of pancreatic cancer cells and the expression 
levels of the GLUT1, GLUT4, as well as those of other glycolytic 
enzymes such as hexokinase II and lactate dehydrogenase A. Thus 
the impairment of the glycolytic metabolism is supposed to be 
responsible of the cytotoxic action exerted by these extracts in 
tumour cells. These effects probably led to the observed reduced 
glucose uptake, rather than a direct inhibition of the GLUTs by 
Graviola extracts.
61
  
 
Synthetic GLUT inhibitors 
 
Enolic anilide Fasentin 32 (Figure 3) was identified as a 
GLUT1/GLUT4 inhibitor by a cell-based high-throughput screening 
to identify small molecules able to restore sensitivity of tumour 
cells to tumour necrosis factor (TNF) family death receptors and 
ligands.
62
 Fasentin partially inhibits glucose uptake at the same 
concentration at which it sensitizes cells to FAS, a death receptor 
belonging to the TNF family that is present on the surface of cells 
and leads to apoptosis. This suggests that fasentin acts by 
promoting intracellular glucose deprivation in leukemia U937 cells 
and prostate PPC-1 cells. Docking studies by using a GLUT1 
homology model revealed that fasentin binds to the 
intramembrane channel of the protein. Moreover, its preferential 
inhibition of GLUT4 was assessed by observing that fasentin inhibits 
glucose uptake more potently in L6 myoblasts cells, which 
overexpress GLUT4.
63
  
In 2011 the research group of Prof. Giaccia discovered a compound 
able to target GLUT1 and efficiently kill renal cell carcinoma, a 
tumour in which the von Hippel-Lindau (VHL) tumour suppressor 
gene is inactivated (VHL-deficient RCC4 cells), thus making it 
strongly dependent on aerobic glycolysis and consequently on 
GLUT1 activity. In fact, GLUT1 resulted to be overexpressed in these 
cells. Amido-sulfondamido derivative STF-31 (33, Figure 3) impaired 
glucose uptake and, therefore, it induced necrotic cell death in the 
VHL-mutated cells by disrupting their main source of energy. 
Modeling studies predicted the binding of STF-31 within the central 
channel of GLUT1, by establishing strong interactions with Arg126 
and Trp412, which are essential residues for glucose transport.
64
 A 
STF-31 derivative (34, Figure 3) was immobilized to a column with a 
polyethylene glycol amino-alkyl linker introduced at the para 
position of the phenyl sulfonamide terminal moiety and it was used 
to confirm the specific binding of STF-31 to the GLUT1 isoform 
compared to GLUT2 and GLUT3. The immobilized drug only bound 
to GLUT1 from cell lysates of VHL-deficient RCC4 cells. This 
derivative retained activity, as demonstrated in a growth inhibition 
assays in the same cells, where it displayed an IC50 value of 7.9 µM. 
Similarly to its parent compound, 34 also maintained a good level of 
selectivity for VHL-negative vs. VHL-positive cells (selectivity ratio > 
5). The maintained activity was due to a steric tolerance at the 4-
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position of the phenyl sulfonamide moiety, which is oriented 
toward the intracellular entrance of the channel.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Structures of natural compounds that inhibit GLUTs. 
 
Therefore, the introduction of the long chain linker in this position 
did not interfere with the activity of the resulting compound and, at 
the same time, provided a suitable connection point to conjugate 
the compound with a resin to be used for affinity chromatography 
for target identification.
65
 Further in vivo experiments were 
performed with a more soluble STF-31 analogue, whose structure 
has not been disclosed yet: it delayed tumour growth and produced 
a marked decrease in tumour glucose uptake, as demonstrated by 
FDG-PET, without provoking toxicity in the treated animals. 
A series of thiazolidinedione derivatives were developed as GLUT 
inhibitors thanks to the observation that a peroxisome proliferator-
activated receptor γ (PPAR γ) agonist exerted part of its action 
through the inhibition of glucose uptake.
66
 Compounds 35 and 36 
(Figure 3) proved to block glucose uptake by LNCaP prostate cancer 
cells. In particular, compound 35 showed an improved activity 
compared to compound 36 (IC50 = 2.5 µM for 35 versus 6 µM for 36) 
and the same trend was observed in the suppression of cell viability 
by inducing apoptosis, without affecting prostate and mammary 
epithelial cells. The specific action of these compounds on GLUT1 
was confirmed by assessing that LNCaP cell line mostly expressed 
GLUT1. Moreover, these cancer cells were transfected with 
plasmids encoding specific GLUT isoforms and the two compounds 
proved to inhibit glucose uptake preferentially in GLUT1-
overexpressing LNCaP cells, with IC50 values very close to those 
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measured in the original cell line (IC50 = 2 µM for 35 versus 5 µM for 
36). Instead, weaker inhibition levels were found in cells transfected 
with GLUT3, GLUT4 and GLUT9, thus confirming that GLUT1 is the 
predominant isoform targeted by these compounds. Docking 
simulations revealed a binding site for compound 35 which is 
different from that of glucose. In fact, compound 35 seems to 
occupy the central part of the intermembrane channel and bind the 
transporter mostly by electrostatic and π-π stacking interactions. 
Further detailed studies were performed on compound 36 and it 
proved to be able to restore the sensitivity to gemcitabine in drug-
resistant pancreatic cancer cells, by enhancing gemcitabine-induced 
DNA damage and inhibiting cell survival. Compound 36 abrogated 
the DNA damage response by inhibiting the activation of some 
factors involved in DNA reparation, thus increasing the efficacy of 
gemcitabine. The synergism with gemcitabine was demonstrated 
also in vivo: the co-administration of the two drugs reduced tumour 
growth to a greater extent than the treatment with the two 
compounds alone, without any evident signs of toxicity in treated 
mice.
67
  
A series of methyl-ketoxime derivatives based on a salicylic scaffold, 
possessing a chlorine atom in position 3 of the central ring and a 
substituted phenyl ring in position para to the oxime group, proved 
to be active as GLUT1 inhibitors. These compounds (37-41, Figure 3) 
display a high similarity with many other GLUT1 inhibitors reported 
in literature, since most of them have similarly-spaced phenol-type 
hydroxy groups.
68,69
 This class of compounds was originally 
designed as estrogen receptor (ER) ligands, but luckily 4-aryl-
substituted salicylketoximes, such as compounds 37-41, did not 
show any relevant biding affinity to estrogen receptors with the 
single exception of compound 38 which displayed a Ki value of 0.4 
µM for ERβ.
70 All the compounds were screened for inhibition of 
glucose transport through GLUT1 by a glucose uptake assay and 
were also subjected to an antiproliferative assay in a human non-
small cell lung cancer cell line. They produced a significant 
reduction of glucose uptake, (IC50 values in the range 10-15 µM), 
and they showed also good cytotoxic activities (IC50 values in the 
range 18-46 µM). In order to confirm the mechanism of action of 
the four most selective GLUT1 inhibitors, the fluorescent glucose 
analogue 2-NBDG was used to visualize and quantify the inhibition 
of glucose uptake in cancer cells by fluorescence microscopy. These 
assays confirmed that ketoximes 37 and 39-41 exerted a more 
potent effect than that of the reference inhibitor phloretin. 
Modeling studies were performed in a homology model of the 
human GLUT1 receptor, built on the basis of the available X-ray 
structure of XylE, an Escherichia coli transporter homologue of 
GLUT1, and they identified three possible binding cavities; in 
particular, the intracellular cavity was identified as the most 
probable binding site of these compounds. 
A library of polyphenolic esters was found to inhibit glucose 
transport and, in particular, compound WZB117 (42, Figure 3) 
proved to be an efficient inhibitor of glucose transport (93% 
inhibition at 30 µM), as well as cancer cell growth (41% inhibition at 
30 µM, IC50 = 10 µM) in H1299 lung cancer cells. Although the 
polyphenolic ester structure of this compound constitutes a 
chemical liability since these groups can readily undergo hydrolytic 
transformations, the activities of these compounds both on glucose 
transport and on cancer cells were demonstrated to be due to the 
unaltered parent ester compounds, since their hydrolysis products 
were completely inactive.
71,72
 The mechanism of action of WZB117 
was specific on GLUT1 isoform, since it inhibited glucose transport 
in human red blood cells, which express uniquely GLUT1. Modeling 
studies suggest the central channel region of the transporter as a 
possible binding site of these molecules, highlighting some 
interactions with important residues of the protein. These inhibitors 
caused a reduction of intracellular ATP and extracellular lactate 
concentration, due to a decreased glycolytic flux, and this finally led 
to cell-cycle arrest and necrosis. The antiproliferative activity of 
WZB117 was further confirmed on a series of cancer cell lines, such 
as non-small cell lung cancer A549 and breast cancer MCF7 cells, 
without affecting their non-tumorigenic counterparts, NL20 and 
MCF12A respectively, with a more pronounced effect under hypoxic 
conditions. A daily intraperitoneal injection of this inhibitor at 10 
mg/kg in an A549 xenograft model of human lung cancer induced a 
reduction of the tumour volume of more than 70% compared to the 
control group, while producing only mild and temporary 
hyperglycemia in the animal.
73
  
Very recently, an extensive series of 1H-pyrazolo[3,4-d]pyrimidines 
were discovered as GLUT1 inhibitors by a cell-based HTS screening 
at Bayer Pharma AG, in which the colorectal adenocarcinoma DLD1 
cells were co-incubated with both the potential GLUT1 inhibitors 
and the oxidative phosphorylation inhibitor rotenone, in order to 
directly correlate the ATP production detected in cells with the 
amount of internalized glucose.
74
 Further cell-based studies 
revealed the competitive behavior of these compounds and their 
selectivity for GLUT1 over the other two main isoforms, GLUT2 and 
GLUT3. The representative compound 43 reported in Figure 3 
possess some structural motives that resulted to be essential by 
SAR studies, such as: a) the ortho-methoxy group of the aryl ring 
connected to the piperazine; b) the central piperazine ring; c) the 
pyrazolo-pyrimidine scaffold; d) the presence of an electron-
withdrawing group, like a fluorine atom, in the ortho position of the 
phenyl ring connected to the pyrazole. All these structural moieties 
led to an optimal balance between GLUT1 inhibition potency (IC50 = 
0.007 µM) and excellent or moderate selectivity over GLUT2 (IC50 = 
1.1 µM) and GLUT3 (IC50 = 0.04 µM). This compound showed a good 
permeability in Caco-2 cells and a suitable metabolic stability in 
pharmacokinetic assays performed in human liver microsomes and 
rat hepatocytes. The promising in vivo PK profile of this GLUT1 
inhibitor revealed a low blood clearance and a good oral 
bioavailability (67%), indicating a complete absorption, together 
with a high volume of distribution and an intermediate terminal 
half-life. 
Some quinazoline-based compounds were patented as GLUT1 
inhibitors, but their target selectivity was low since most of them 
are also activators of AMPK, and/or inhibitors of protein kinase 2 
(CK2) and Rho kinase (ROCK2). For example, compound 44 reported 
in Figure 3 is active on all the four targets and, in particular, it 
produced an inhibition of glucose consumption greater than 90% at 
10 µM in fibrosarcoma HT1080 cells. This inhibitor was 
administered to mice fed with a high fat diet provoking an increase 
in fatty acid oxidation and blood glucose level, probably indicating a 
reduced cellular uptake of glucose.
75
  
The structurally simple curcumin analogue EF24 (45, Figure 3) 
exerted antiproliferative and anti-angiogenic effects on a wide 
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panel of cancer cells and it induced tumour regression in nude 
mice.
76
 Moreover, EF24 induced cell cycle arrest and apoptosis by 
means of a redox-dependent mechanism in MDA-MB-231 human 
breast and DU-145 human prostate cancer cells,
77
 and inhibited HIF-
1.
78
 In 2013, it was demonstrated that EF24 exerted an anticancer 
effect also on ovarian cancer by targeting GLUT1. As a matter of 
fact, a 3 µM concentration of this molecule suppressed the 
proliferation and the invasivity of three ovarian cancer cells (SKOV-
3, A2780 and OVCAR-3 cells), and it also influenced the metabolism 
by reducing glucose uptake, the rate of glycolysis and lactate 
production. These effects seem to be mediated by GLUT1 
downregulation. The in vivo efficacy of EF24 was demonstrated in a 
xenograft tumour model, in which treatment with this compound 
decreased the growth of tumours and the number of 
intraperitoneal and lung metastases of SKOV-3 shControl cells more 
evidently than those produced by tumours of SKOV-3 shGLUT1 
cells, thus suggesting that the anticancer activity of EF24 is 
mediated by GLUT1.
79
  
Kapoor et al. identified a couple of new GLUT1 inhibitors based on a 
phenylalanine amide scaffold by a cell-based ultrahigh-throughput 
screening and these compounds were co-crystallized with human 
GLUT1 in the inward-open conformation (compounds 46 and 47, 
Figure 3). They potently inhibited glucose transport with IC50 values 
in the nanomolar range. In particular, compound 47 was more 
efficient in block the glucose uptake through GLUT1 (IC50 = 140 nM) 
than compound 46 (IC50 = 267 nM), but it was also more active in 
isoform GLUT4 (IC50 = 90 nM) compared to compound 46 (IC50 = 195 
nM). Both the compounds were less potent on transporters GLUT2 
and GLUT3. An X-ray study revealed that the binding sites of the 
newly discovered inhibitors, as well as that of cytochalasin B, 
overlap each other in the glucose site of the central cavity, despite 
the different chemical structures of these molecules. Amidic 
inhibitor 46 showed π-π interactions between its terminal phenyl 
and phenol rings and Trp388, as well as between the central fluoro-
substituted phenyl ring and Phe379. Moreover, both the inhibitors 
46 and 47 established hydrophobic interactions with Asn411 and 
Trp412. A determinant role was identified for Trp88 because it is 
conserved in all the GLUT family and its binding with the substrate 
glucose probably induces the closure of the central cavity of the 
transporter. Therefore, interactions of inhibitors with this residue 
may hinder the movement of the loop that closes the cavity and, 
therefore, block the flux of glucose through the transporter.
80
  
Although a crystal structure of human GLUT1 in an inward open 
conformation was recently deposited,
81
 Ung and co-workers built a 
homology model of GLUT1 in the partially occluded outward open 
conformation, based on the X-ray structure of the E. coli xylose 
transporter, XylE. The occluded XylE structure is a suitable template 
thanks to its high resolution and limited dimensions, thus it can help 
to understand the interactions involved in substrate binding. This 
study revealed the presence of a hydrophobic pocket adjacent to 
the polar substrate binding site, which partially overlaps with the 
sugar-biding site. After the construction and the validation of the 
homology model by site-directed mutagenesis studies, a virtual 
screening of commercially available compounds was performed, 
focusing on the top-ranking compounds that interact in the glucose-
biding site and in the newly discovered hydrophobic pocket. Among 
the eight best compounds, the xanthine derivative PUG-1 (48, 
Figure 3) proved to be a potent inhibitor of glucose transport, 
showing an IC50 value of 450 nM in the [
3
H]-2-deoxy-D-glucose 
uptake assay in the Chinese hamster ovary CHO cell line 
overexpressing GLUT1, and a high ligand efficiency value. PUG-1 
was predicted to establish many hydrogen bonds in the sugar 
binding site as well as occupying the hydrophobic pocket. 
Moreover, it seems to interact with transmembrane helix 10, which 
strongly influences the size of the sugar binding site by shifting it in 
the outward open conformation and, therefore, blocking the 
channel portion between the substrate binding site and the cytosol. 
A pyridazinone-based compound PUG-7 (49, Figure 3) also resulted 
as a hit from the same virtual screening in spite of displaying a 
chemical structure which is quite different from those of the other 
GLUT1 inhibitors found. However, its inhibitory potency in the 
glucose uptake assay was lower (IC50 value of 11.8 µM) than that of 
PUG-1 probably because, due to its compact structure, it does not 
reach the hydrophobic pocket.
82
 
 
Sugar-conjugate compounds interacting with 
GLUTs 
The conjugation of anticancer agents with glucose or different sugar 
portions is a widely exploited technique to design therapeutic 
agents, in order to improve their uptake into highly glycolytic 
cancer cells overexpressing GLUTs.
7 Some of these agents take 
advantage of the sugar-conjugation to be internalized through GLUT 
receptors into the cancer cells without inhibiting GLUTs themselves. 
The glucose-conjugated S-nitroso-N-acetyl-penicillamine 2-Glu-
SNAP 50 (Figure 4) was initially designed as a nitric oxide (NO) 
releasing compound, in which the carbohydrate unit linked through 
its 2-position has the function of enhancing its pharmacokinetic 
properties.
83
 This molecule exerted a marked cytotoxic effect in 
both cisplatin-sensitive (A2780S) and insensitive (A2780cP) human 
ovarian cancer cell lines, with IC50 values of 4.2 and 380 nM, 
respectively, and the different sensibility to 2-Glu-SNAP was 
explained considering the higher expression of GLUT1 in A2780S 
cells, although no better explanations were given about the 
possible mechanism of 2-Glu-SNAP cytotoxicity. 2-Glu-SNAP was 
5000-fold more effective than the NO-donating moiety (SNAP) 
alone in A2780S cells, suggesting that the glucose moiety is 
responsible of the improved uptake into cancer cells.
84
 2-Glu-SNAP 
also proved to inhibit proliferation preferentially in GLUT1-
overexpressing glioblastoma cell line T98G, while a GLUT1-deficient 
osteoblastoma cell line and its mitochondria-deficient variant rhoo 
cell line were only minimally affected, thus confirming the previous 
hypothesis.
85
  
Glucophosphamide 51 (Figure 4) is a DNA alkylating agent in which 
the isophosphoramide mustard, the cytotoxic metabolite of this 
drug, is covalently linked to glucose. Its anticancer potency was 
reduced if cells were co-treated with GLUT1 inhibitors, suggesting 
that its entry into the cells is mediated by GLUT1.
86 
It possesses a 
favorable safety profile and an evident anti-tumour activity in many 
resistant and advanced carcinomas overexpressing GLUT1, and 
many clinical trials demonstrated its efficacy and relative selectivity 
for cancer cells.
87,88
 Recently, two phase 2 studies of the efficacy 
and safety of glucophosphamide in previously treated advanced 
soft tissue sarcoma and in ovarian cancer were terminated 
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(https://www.clinicaltrials.gov/ct2/search last access in February 
2
nd
 2016), although they displayed a certain degree of adverse 
events associated to its administration. Now glucophosphamide is 
being studied in a phase 3 study in comparison with fluorouracil (5-
FU) in patients with metastatic pancreatic adenocarcinoma 
previously treated with gemcitabine.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structures of synthetic compounds that inhibit GLUTs. 
 
The anticancer drug paclitaxel is widely used for the treatment of 
breast, ovarian, and lung carcinomas, but its low water solubility 
has severely reduced its clinical application. Among the many 
adopted strategies to improve its pharmacokinetic properties, the 
glycoconjugation of paclitaxel led to a derivative in which the C-2’ 
hydroxyl group of the drug was linked to a 1-methyl glucose 
molecule via a short succinic acid linker (52, Figure 4).
89
 This new 
prodrug was designed to enhance the solubility, as well as to 
selectively deliver it to cancer versus normal cells by a preferential 
uptake via GLUTs. The resulting compound, whose transport was 
mediated at least in part by GLUT1 as confirmed by fluorescence 
microscopy studies, showed improved pharmaceutical properties 
and a comparable cytotoxicity against MCF-7 breast cancer cells 
without toxicity on normal cells, but it showed a reduced toxicity on 
most of the tested cancer cell lines compared to the parent 
compound.
90
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Calvaresi et al. discovered a glucose-conjugated methyl ester N-
hydroxyindole 53 (Figure 4), which inhibits hLDH5 with a Ki value of 
37.8 µM. This inhibitor proved to be able to cross the cytoplasmatic 
membrane very efficiently by means of GLUT1, which allowed its 
preferred uptake by cancer cells, as demonstrated by confocal laser 
scanning microscopy studies by using a fluorescent bioprobe that 
competes for cellular entry through GLUT transporters. 
Unfortunately, the conjugation with glucose made this hLDH5 
inhibitor weaker than the N-OH analogue aglycone (Ki = 5.1 µM) on 
the isolated enzyme. Furthermore, the glycoconjugate N-
hydroxyindole-based compound efficiently reduced lactate 
production in HeLa cells and compromised cell proliferation in 
several cancer cell lines.
91
  
The platinum antitumour drug oxaliplatin is a commonly used 
chemotherapeutic agent applied in clinics especially for colorectal 
cancer, however its multiple side effects severely limited its 
benefits. The conjugation with sugar portions was introduced as a 
strategy to improve the tumour-targeting ability of the drug and 
also to enhance its water solubility, thus it can be excreted intact by 
the kidneys and avoid systemic toxicity. The glucosylated (trans-R,R-
cyclohexane-1,2-diamine)-malonatoplatinum(II) derivative 54 
(Figure 4) showed an increased cytotoxicity compared to oxaliplatin 
in all the tested human carcinoma cell lines. Its potency was 
prevented when human colon cancer (HT29) and breast cancer 
(MCF7) cells, which overexpress GLUTs, were treated with GLUT 
inhibitor phlorizin, thus confirming that the uptake and the 
antiproliferative activity of this compound are mediated by GLUT 
transporters.
92
  
A further development of this platinum conjugate was obtained 
with the synthesis of galactose-platinum(II) complex 55 (Figure 4), 
in which platinum(II) is chelated by the same ligand trans-R,R-
cyclohenxane-1,2-diamine. This compound was recently evaluated 
in human cancer cell lines and against two different xenograft 
tumour models.  The results observed in human colon cancer HT29 
cells by using GLUT inhibitor quercetin highlighted that, in the 
presence of the GLUT inhibitor the antiproliferative activity of 
galactose-platinum complex was highly reduced, suggesting that 
the uptake of the complex was regulated by GLUT. These results 
were confirmed by further competition assays by using fluorescent 
glucose bioprobe 2-NBDG: a 20 µM concentration of the Pt-complex 
resulted in a 30% decrease in 2-NBDG uptake, compared to HT29 
untreated cells.
93
  
Some glyco-conjugated molecules reach their intracellular target by 
using GLUT-mediated transport, but at the same time they also 
directly inhibit or interact with GLUTs. An example is represented 
by the glucose-chlorambucil derivative 56 (Figure 5), where the 
alkylating portion is linked to the hydroxy group in position 6 of the 
glucose molecule to facilitate its delivery to the tumor. This 
derivative inhibits the D-[
14
C]glucose uptake by GLUT1 in human 
erythrocytes by a reversible and competitive mechanism (IC50 = 65 
µM), thus excluding any alkylating mechanism on the transporter 
protein. The presence of the ester moiety and of the free anomeric 
group seems to be essential for its activity on GLUT, since both the 
amidic analogue and the derivative bearing a methoxy group at the 
anomeric position were less active.
94
 
In 1997 a series of glycoconjugate analogues of the alkylating 
antineoplastic agent busulfan were synthesized, with the aim of 
improving selectivity and brain penetration to overcome the 
problem of poor uptake into the central nervous system of 
chemotherapeutic agents against cerebral tumours. In particular, 
the 4-O-methylsulfonyl-D-glucose 57 (Figure 5) proved to inhibit D-
[
14
C]glucose uptake into the human erythrocyte by GLUT1 
transporter, but its potency as GLUT inhibitor was very low (IC50 = 
32 mM).
95
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Structures of sugar-conjugated compounds entering the 
cell by GLUTs. 
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Kumar et al. reported a 2-nitroimidazolyl−glucose conjugate 
coupled at C6-O of glucose via a propyl linker (58, Figure 5). This 
glucoazomycin was developed as a hypoxia-selective radiosensitizer 
and the sugar moiety was introduced with the aim of reducing the 
toxicity of the classical 2-nitroimidazoles by improving cancer cell 
selective delivery. Compound 58 was shown to bind the transporter 
and to compete with D-[
14
C]glucose uptake in Xenopus oocytes 
expressing GLUT1, with a weak ED50 of approximately 0.5 mM. This 
compound also proved to be an effective radiosensitizer in multiple 
cancer cell lines using radiation doses up to 18 Gy.
96
  
The anthracycline antitumor antibiotic doxorubicin conjugated via a 
succinic spacer with a 2-amino-2-deoxy-glucose portion 59 (2DG-
SUC-ADM, Figure 5) was designed to enhance the selectivity of 
doxorubicin against cancer cells and to reduce its toxicity to healthy 
cells. Its uptake resulted to be mostly mediated by GLUT1, since it 
was significantly inhibited by 2-deoxyglucose or quercetin in the 
human liver carcinoma HepG2 cells. The GLUT1-mediated transport 
inside cells explained the specificity of 2DG-SUC-ADM: it exerted an 
antiproliferative effect in cancer cells but, unlike doxorubicin alone, 
it was not cytotoxic for human embryonic lung fibroblast HELF cells. 
In fact, the uptake of free doxorubicin mainly occurs through 
molecular diffusion, whereas the uptake of 2DG-SUC-ADM is mostly 
mediated by GLUT1. Similarly, in vivo studies demonstrated that 
this conjugate significantly decreased systemic toxicity and 
enhanced the antitumor efficacy compared with free aglycone 
doxorubicin.
97
  
A cell-based screening led to the discovery of two synthetic 
carbasugars 60 and 61 (Figure 5) that inhibited glycolysis by 
blocking glucose uptake in a dose-dependent manner, without 
interfering with other two glycolytic enzymes, such as hexokinase 
and pyruvate kinase, although in this case the authors did not 
mention any possible direct inhibition of GLUTs.
98
  
 
Conclusions 
 
Glucose transporters are currently being considered as some of the 
most relevant glycolytic effectors, which may be profitably targeted 
by innovative therapeutic interventions aimed at treating tumours. 
Their several-fold overexpression in cancer cells, when compared to 
normal cells, should guarantee a safe therapeutic window and, 
therefore, a selective cytotoxic effect of compounds that are able to 
interact with these transporters. In fact, the high efficiency of the 
glucose uptake by cancer cells has been successfully exploited for 
the selective delivery of various types of anticancer agents. 
Furthermore, the remarkable addiction displayed by cancer cells for 
sugars has led to the development of various classes of GLUT-
inhibitors as perspective novel and selective anticancer drugs. 
Nevertheless, a certain degree of side effects may be expected, 
especially those occurring in organs characterized by high glucose-
consumption rates, such as the brain. In any case, it is known that in 
starvation ketone bodies produced by the liver can replace glucose 
as fuel for the brain, whereas highly glycolytic cancer cells should 
not be able to fully utilize them. Therefore, a combined 
administration of glucose-interfering agents with either a ketogenic 
diet or dietary supplements such as triheptanoin (which is currently 
being tested for the treatment of GLUT1 deficiency
99
), should 
improve the safety profile of these compounds.  
Finally, the recent publication of X-ray structures of these 
transporter will be of invaluable value in the near future for the 
refinement of the molecular modeling approaches dedicated to the 
discovery of more potent and selective inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Structures of sugar-conjugated compounds that inhibit 
GLUTs. 
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